Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment

Abstract: In patients with paroxysmal nocturnal hemoglobinuria (PNH), the complement component 5 (C5) inhibitors ravulizumab and eculizumab control terminal complement activity and intravascular hemolysis, which are drivers of morbidity and mortality. During C5 inhibitor treatment, ongoing C3 fragme...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Austin G. Kulasekararaj, Jong Wook Lee, Christopher J. Patriquin, Caroline I. Piatek, Alexander Röth, Wilma Barcellini, Robert A. Brodsky, Jun-ichi Nishimura, Ji Yu, Mohammed Mahdi, Régis Peffault de Latour
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2025-10-01
Serier:	Blood Advances
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2473952925002502
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!